High Specificity Single Domain Antibody (SdAb) Discovery Service for Improving Targeted Delivery

The advancement of innovative targeted therapeutic strategies is anticipated to exceed the efficacy of current treatments while minimizing collateral damage to healthy cells adjacent to the target sites. Monoclonal antibodies (mAbs) have been utilized to directly inhibit tumor growth and proliferation or to deliver effector molecules to tumor cells. However, the effectiveness of this delivery method is limited by the large size of mAbs (~150 kDa), which hinders their ability to penetrate tumor tissue effectively. Recently, single domain antibodies (sdAbs) have been proposed as targeting moieties for the development of novel drug delivery systems or as intracellular targeting agents for preclinical evaluation. Creative Biolabs offers high-specificity sdAb discovery services to meet the enhanced requirements for targeted delivery.

SdAb as Targeting Moiety for Drug Delivery

Single domain antibodies (sdAbs) are emerging as next-generation targeting moieties and represent the smallest naturally occurring antibodies with the ability to recognize diverse antigen epitopes in the nanomolar range. Their compact, single-domain structure allows them to remain chemically active in the cell's reducing environment and facilitates better diffusion through tissues and intracellularly across nuclear pores. Beyond their single-digit nanometer dimensions, sdAbs exhibit unique characteristics such as high stability and solubility, low immunogenicity, and exceptional affinity and specificity for various targets, including tumor markers. Consequently, sdAbs are deemed exceptionally suitable as targeting moieties for delivering various compounds to meet applications in either diagnostic or therapeutic purposes.

It is well-recognized that the targeted delivery of anti-tumor substances can enhance therapeutic efficacy and reduce side effects. A standard targeted drug delivery platform consists of Payload (targeting ligand), Linker (drug carrier), and Drug (pharmaceutical substance). To date, a diverse array of sdAbs has been developed against a wide range of molecular targets. Single domain antibodies are frequently employed as the Payload to precisely direct the Drug to specific lesions. Drug delivery systems utilizing sdAbs facilitate the transport of specific agents to either extracellular tumor targets or highly promising intracellular biomarkers.

To date, the majority of applications have utilized single domain antibodies (sdAbs) targeting extracellular molecules. Nonetheless, intracellular effectors, such as signaling pathways, are also considered promising therapeutic targets for sdAbs. Proposed strategies include the use of lentiviral vectors and bacterial type III secretion systems to deliver sdAbs specifically into tumor cells, thereby inhibiting intracellular tumor markers. The ease of engineering sdAbs allows for the recognition of various cell types, and advancements in display technology will further augment their potential in gene therapy, tumor immunotherapy, and intracellular targeting.

By targeting the specific receptors in tumor cells, sdAbs have been employed as targeting moieties for the delivery of imaging for diagnostics or therapeutic agents for improving therapeutic efficacy. Creative Biolabs has years of experience in sdAb development, providing a high-quality sdAb based ADC development service to meet your specific demands. If you have additional questions or would like to consult with the experts at Creative Biolabs, please contact our team.

We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.

Online Inquiry
Interested in our expertise?

Contact us for more information

Get free consultations
USA
  • Tel:
  • Fax:
  • Email:
UK
  • Tel:
  • Email:
Germany
  • Tel:
  • Email:

Enter your email here to subscribe.

Submit

Follow us on

ISO 9001 Certified - Creative Biolabs Quality Management System.
Copyright © 2025 Creative Biolabs. All Rights Reserved.